NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-08-31
Reading BIIB? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Biogen manages a mid-single digit revenue decline in 2026. It invests in growth through acquisitions like Apellis and RayThera. Earnings per share are expected around $14.75 in 2026 and $16.63 in 2027. Profit margins remain stable with steady cash flow.
Revenue decline could worsen beyond mid-single digits. Investment in growth may not pay off due to pipeline cuts. Earnings could fall short of $14.25 to $15.25 per share in 2026. Legal and management changes may disrupt execution.
The market expects about 3% revenue growth and prices the stock roughly 26% below our valuation model's midpoint. Our view is more optimistic on earnings growth and successful integration of acquisitions.
Breaks if: FCF yield falls below 8%
Breaks if: EPS falls below $14.25 in FY26 or below $16.63 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on sustainable revenue growth and pipeline advancement. The current thesis state is intact, supported by recent earnings beats and a solid growth portfolio.
The market currently prices BIIB as justified, with a low fragility tier. It is seen as cheap compared to peers, indicating that expectations may not be overly optimistic.
Management is on track to drive revenue growth through portfolio expansion, with recent financial performance showing strength. However, there are mixed signals regarding the advancement of the late-stage pipeline and integration of the Apellis Pharmaceuticals acquisition.
The thesis hinges on the performance of sector bellwethers and whether BIIB can maintain or improve guidance in the upcoming earnings call. Additionally, the impact of broader economic conditions, such as job reports, could influence sentiment.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'favorable'.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company is expanding its growth portfolio. It is also advancing its late-stage pipeline with key data readouts. There are no new threats impacting the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Significant setbacks or pipeline reductions from acquisitions
Breaks if: revenue decline exceeds 5% YoY in FY26
Biogen aims to manage a mid-single digit percentage decline in total revenue for 2026 compared to 2025.
Over the next 1 to 3 years, BIIB's performance will depend on its ability to execute on growth initiatives and navigate sector dynamics. Not investment advice.
